All News I-Mab

Equities

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
1.8 ^USD	-0.55%		0.00%	-5.26%

18/04	Verastem Names John Hayslip as Chief Medical Officer	MT
15/04	I-Mab Announces Chief Medical Officer Changes	CI

Verastem Names John Hayslip as Chief Medical Officer	19/04	MT
I-Mab Announces Chief Medical Officer Changes	16/04	CI
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	08/04	AQ
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	05/04	PR
I-Mab Completes Business Divestiture in China	03/04	MT
I-Mab Announces Closing of the Divestiture of Business Operations in China	03/04	PR
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.	02/04	CI
I Mab : Resignations of Director and Senior Management - Form 6-K	01/04	PU
I-Mab Announces Executive Resignation	01/04	CI
Piper Sandler Adjusts Price Target on I-Mab to $10 From $15, Maintains Overweight Rating	18/03	MT
Needham Cuts Price Target on I-Mab to $6 From $8, Maintains Buy Rating	15/03	MT
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02	RE
I-Mab Divests China Operations, Shifts Focus to US Market	09/02	MT
ADRs Close Higher, Renalytix PLC Climbs 96.9%	09/02	DJ
I-Mab Signs Agreement to Divest its Assets and Business Operations in China	08/02	AQ
Biotech firm I-Mab to divest China operations, shift focus to US	07/02	RE
Biotech firm I-Mab to divest China operations	07/02	RE
I-Mab Announces Board Changes , Effective February 10, 2024	07/02	CI
I-mab Biopharma Co., Ltd. announced that it expects to receive CNY 19 million in funding from I-Mab	07/02	CI

No results for this search